MECOM and leukemia: While significant traction has been gained in dissecting some of the mechanisms via which EVI1 expression is deregulated in leukemia, so far there appears to be little consensus in the literature on the critical downstream effects of EVI1 that relate to the evolution of therapy-resistant hematologic malignancies.